2nd Quarter - Report

ADVANCED MEDICAL TECHNOLOGY ASSN for ADVANCED MEDICAL TECHNOLOGY ASSN

Firm
Client
Income
—
Expenses
$880,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues related to coverage of telehealth services Issues related to Medicare coverage for digital health technologies Issues related to physician fee schedule Issues related to H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act Issues related to S. 1000/H.R. 2377 Saving Access to Laboratory Services Act

LobbyistCovered position, as disclosed
GREG MICHAEL CRIST —
NICK HALSTED New —
SARAH KILLEEN —
AMANDA WALSH —
KIM ZIMMERMAN —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1691 (118th), H.R. 2377 (118th), S. 1000 (118th)

Health Issues HCR

Issues related to Privacy Legislation Issues related to the medical supply chain Issues related to the competitiveness of the medtech industry and the impact of Federal Policies Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to coverage and reimbursement of diagnostic tests VALID Act of 2023 - H.R. 2369. Issues related to Health Equity Issues related to Public Health Emergency Preparedness (including Pandemic All Hazards Preparedness Act reauthorization) Issues related to the use of Artificial Intelligence Issues related to MDUFA Reauthorization Issues related to PFAS Chemical regulation HR 3723 - the Medical Device Electronic Labeling Act HR 5662/S 2907 - the Medical Device Recall Improvement Act S 2672 - Improving Development and Distribution of Diagnostic Tests Act HR 3795 - Diagnostic Testing Preparedness Plan Reimbursement and coverage of focused ultrasound technology HR 1328, the Medical Device Nonvisual Accessibility Act of 2023 Issues related to FDAs third party review program

LobbyistCovered position, as disclosed
GREG MICHAEL CRIST —
NICK HALSTED New —
SARAH KILLEEN —
ALEXANDRA MILLER New —
AMANDA WALSH —
KIM ZIMMERMAN —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS); SENATE; Office of Management & Budget (OMB); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA)

Bills named: H.R. 2369 (118th), H.R. 3795 (118th), H.R. 1328 (118th), H.R. 5662 (118th), H.R. 3723 (118th)

Budget/Appropriations BUD

Issues related to appropriations and user fee funding for the Food and Drug Administration

LobbyistCovered position, as disclosed
GREG MICHAEL CRIST —
NICK HALSTED New —
SARAH KILLEEN —
AMANDA WALSH —
KIM ZIMMERMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Issues related to R&D Expense Amortization

LobbyistCovered position, as disclosed
GREG MICHAEL CRIST —
NICK HALSTED New —
SARAH KILLEEN —
AMANDA WALSH —
KIM ZIMMERMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Issues related to TRIPS Waiver Extension

LobbyistCovered position, as disclosed
GREG MICHAEL CRIST —
NICK HALSTED New —
SARAH KILLEEN —
AMANDA WALSH —
KIM ZIMMERMAN —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Office of Management & Budget (OMB); SENATE; Natl Security Council (NSC); Commerce, Dept of (DOC)

Small Business SMB

Issues related to the reauthorization of the Small Business Innovation Research (SBIR) program.

LobbyistCovered position, as disclosed
GREG MICHAEL CRIST —
SARAH KILLEEN —
AMANDA WALSH —
KIM ZIMMERMAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.